BSX Valuation

Boston Scientific Corp

Add to Watchlist

Advanced Chart

106.140

-0.07(-0.066%)1D

Overview
Forecast
Valuation
Earnings

BSX Relative Valuation

BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BSX is overvalued; if below, it's undervalued.

Historical Valuation

Boston Scientific Corp (BSX) is now in the Overvalued zone, suggesting that its current forward PE ratio of 34.21 is considered Overvalued compared with the five-year average of 26.69. The fair price of Boston Scientific Corp (BSX) is between 77.71 to 98.61 according to relative valuation methord. Compared to the current price of 106.14 USD , Boston Scientific Corp is Overvalued By 7.64%.

Relative Value

Fair Zone

77.71-98.61

Current Price：106.14

7.64%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

7.07

P/B

Median3y

4.99

Median5y

4.43

0.00

FCF Yield

Median3y

1.55

Median5y

1.82

Competitors Valuation Multiple

The average P/S ratio for BSX's competitors is 7.32, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX) exhibits a P/S ratio of 7.54, which is 3.08% above the industry average. Given its robust revenue growth of 22.84%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BSX.N

Boston Scientific Corp

7.54

Average P/S: 7.32

22.84%